Related Experiment Videos
Primitive hematopoietic stem cell function in vivo is uniquely high in the CXB-12 mouse strain
J Chen1, C M Astle, C E Müller-Sieburg
1The Jackson Laboratory, Bar Harbor, ME 04609, USA.
Blood
|December 9, 2000
Summary
Bone marrow cells from CXB-12 mice exhibit superior long-term repopulating ability compared to other recombinant inbred lines. This enhanced hematopoietic stem cell function suggests potential for improved cell therapies.
Area of Science:
- Hematology
- Immunology
- Genetics
Background:
- Recombinant inbred (RI) lines are valuable tools for dissecting genetic contributions to complex traits.
- Hematopoietic stem cell (HSC) function is critical for maintaining blood cell production and is influenced by genetic factors.
Purpose of the Study:
- To evaluate and compare the long-term repopulating ability of bone marrow cells (BMCs) from different CXB RI lines.
- To identify genetic factors contributing to superior HSC function in specific RI lines.
Main Methods:
- Bone marrow cells (BMCs) from CXB RI lines were competitively transplanted into lethally irradiated recipients along with genetically marked competitor BMCs.
- Donor-derived cell percentages (erythrocytes, lymphocytes) were measured at various time points to assess repopulating function.
- Quantitative modeling was used to determine the number and function of hematopoietic stem cells (HSCs).
Main Results:
- CXB-12 BMCs demonstrated significantly higher long-term repopulating ability (up to 14 times) compared to 11 other CXB RI lines.
- CXB-12 cells showed a 3 to 12-fold advantage over standard competitor cells, with increased efficacy at higher cell doses.
- Modeling indicated CXB-12 donors possess 2.4 times the HSC concentration and 1.4 times the function per HSC compared to the standard.
Conclusions:
- CXB-12 mice harbor unique genetic factors that confer superior hematopoietic stem cell (HSC) number and function.
- These findings highlight the potential of specific RI lines for understanding genetic regulation of HSCs and for developing novel cell-based therapies.